Increased burden of cardiovascular disease in carriers of APOL1 genetic variants
- PMID: 24379297
- PMCID: PMC3982584
- DOI: 10.1161/CIRCRESAHA.114.302347
Increased burden of cardiovascular disease in carriers of APOL1 genetic variants
Abstract
Rationale: Two distinct alleles in the gene encoding apolipoprotein L1 (APOL1), a major component of high-density lipoprotein, confer protection against Trypanosoma brucei rhodesiense infection and also increase risk for chronic kidney disease. Approximately 14% of Americans with African ancestry carry 2 APOL1 risk alleles, accounting for the high chronic kidney disease burden in this population.
Objective: We tested whether APOL1 risk alleles significantly increase risk for atherosclerotic cardiovascular disease (CVD) in African Americans.
Methods and results: We sequenced APOL1 in 1959 randomly selected African American participants in the Jackson Heart Study (JHS) and evaluated associations between APOL1 genotypes and renal and cardiovascular phenotypes. Previously identified association between APOL1 genotypes and chronic kidney disease was confirmed (P=2.4×10(-6)). Among JHS participants with 2 APOL1 risk alleles, we observed increased risk for CVD (50/763 events among participants without versus 37/280 events among participants with 2 risk alleles; odds ratio, 2.17; P=9.4×10(-4)). We replicated this novel association of APOL1 genotype with CVD in Women's Health Initiative (WHI) participants (66/292 events among participants without versus 37/101 events among participants with 2 risk alleles; odds ratio, 1.98; P=8.37×10(-3); JHS and WHI combined, P=8.5×10(-5); odds ratio, 2.12). The increased risk for CVD conferred by APOL1 alleles was robust to correction for both traditional CVD risk factors and chronic kidney disease.
Conclusions: APOL1 variants contribute to atherosclerotic CVD risk, indicating a genetic component to cardiovascular health disparities in individuals of African ancestry. The considerable population of African Americans with 2 APOL1 risk alleles may benefit from intensive interventions to reduce CVD.
Keywords: atherosclerosis; continental population groups; epidemiology; genetics; renal insufficiency, chronic; risk factors.
Conflict of interest statement
The authors have no competing financial interests.
Figures


Comment in
-
Cardiovascular twist to the rapidly evolving apolipoprotein L1 story.Circ Res. 2014 Feb 28;114(5):746-7. doi: 10.1161/CIRCRESAHA.114.303354. Circ Res. 2014. PMID: 24577959 Free PMC article. No abstract available.
References
-
- Pollak MR, Genovese G, Friedman DJ. Apol1 and kidney disease. Curr Opin Nephrol Hypertens. 2012;21:179–182. - PubMed
-
- Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–1315. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01WH42119/WH/WHI NIH HHS/United States
- RC2 HL-102926/HL/NHLBI NIH HHS/United States
- N01 WH022110/WH/WHI NIH HHS/United States
- R01 HL080494/HL/NHLBI NIH HHS/United States
- N01WH32111/WH/WHI NIH HHS/United States
- UC2 HL102924/HL/NHLBI NIH HHS/United States
- N01WH42122/WH/WHI NIH HHS/United States
- HL080494-05/HL/NHLBI NIH HHS/United States
- RC2 HL102925/HL/NHLBI NIH HHS/United States
- N01WH42124/WH/WHI NIH HHS/United States
- N01WH32102/WH/WHI NIH HHS/United States
- N01 HC095172/HL/NHLBI NIH HHS/United States
- N01WH42112/WH/WHI NIH HHS/United States
- U54 HG003067/HG/NHGRI NIH HHS/United States
- N01WH32112/WH/WHI NIH HHS/United States
- RC2 HL102926/HL/NHLBI NIH HHS/United States
- N01WH32101/WH/WHI NIH HHS/United States
- N01WH32119/WH/WHI NIH HHS/United States
- N01WH32105/WH/WHI NIH HHS/United States
- N01WH42132/WH/WHI NIH HHS/United States
- N01WH42121/WH/WHI NIH HHS/United States
- N01WH42113/WH/WHI NIH HHS/United States
- N01WH42125/WH/WHI NIH HHS/United States
- N01WH32106/WH/WHI NIH HHS/United States
- N01WH42129/WH/WHI NIH HHS/United States
- T32 GM007753/GM/NIGMS NIH HHS/United States
- N01WH42108/WH/WHI NIH HHS/United States
- N01WH42118/WH/WHI NIH HHS/United States
- N01WH32113/WH/WHI NIH HHS/United States
- HL-102924/HL/NHLBI NIH HHS/United States
- N01WH42120/WH/WHI NIH HHS/United States
- N01WH32118/WH/WHI NIH HHS/United States
- R01MD007092/MD/NIMHD NIH HHS/United States
- N01WH42131/WH/WHI NIH HHS/United States
- RC2 HL102924/HL/NHLBI NIH HHS/United States
- N01WH42109/WH/WHI NIH HHS/United States
- R01 MD007092/MD/NIMHD NIH HHS/United States
- N01WH42114/WH/WHI NIH HHS/United States
- N01WH32122/WH/WHI NIH HHS/United States
- N01WH42107/WH/WHI NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- N01 HC095170/HL/NHLBI NIH HHS/United States
- N01WH42130/WH/WHI NIH HHS/United States
- N01WH42117/WH/WHI NIH HHS/United States
- N01WH42115/WH/WHI NIH HHS/United States
- N01-HC-95171/HC/NHLBI NIH HHS/United States
- R01 HL084553/HL/NHLBI NIH HHS/United States
- RC2 HL-102925/HL/NHLBI NIH HHS/United States
- N01WH42111/WH/WHI NIH HHS/United States
- N01-HC-95172/HC/NHLBI NIH HHS/United States
- N01WH32109/WH/WHI NIH HHS/United States
- N01WH32108/WH/WHI NIH HHS/United States
- U01 HL098166/HL/NHLBI NIH HHS/United States
- N01WH32100/WH/WHI NIH HHS/United States
- N01 HC095171/HL/NHLBI NIH HHS/United States
- N01WH42123/WH/WHI NIH HHS/United States
- N01WH44221/WH/WHI NIH HHS/United States
- N01WH32115/WH/WHI NIH HHS/United States
- N01-HC-95170/HC/NHLBI NIH HHS/United States
- N01WH24152/WH/WHI NIH HHS/United States
- N01WH42110/WH/WHI NIH HHS/United States
- N01WH42126/WH/WHI NIH HHS/United States
- N01WH42116/WH/WHI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous